{"id":76765,"date":"2026-08-27T12:29:21","date_gmt":"2026-08-27T04:29:21","guid":{"rendered":"https:\/\/flcube.com\/?p=76765"},"modified":"2026-08-27T12:29:21","modified_gmt":"2026-08-27T04:29:21","slug":"shionogi-terminates-collaboration-with-susmed-on-digital-insomnia-therapy-med-cbt-i","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76765","title":{"rendered":"Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT\u2011i"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shionogi &amp; Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/4507:TYO\">TYO: 4507<\/a>) announced that it has terminated its collaboration with <strong>SUSMED Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/4263:TYO\">TYO: 4263<\/a>) regarding a <strong>digital therapeutic for insomnia<\/strong>. The two companies originally entered into a commercialization agreement for the therapy in 2021, centered on <strong>SUSMED&#8217;s Med CBT\u2011i<\/strong> application, which delivers <strong>cognitive behavioral therapy for insomnia (CBT\u2011I)<\/strong> to patients.<\/p>\n\n\n\n<h2 id=\"h-deal-milestone\" class=\"wp-block-heading\">Deal Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Parties<\/td><td><strong>Shionogi &amp; Co., Ltd.<\/strong> (TYO: 4507) and <strong>SUSMED Co., Ltd.<\/strong> (TYO: 4263)<\/td><\/tr><tr><td>Event<\/td><td>Termination of collaboration agreement<\/td><\/tr><tr><td>Asset<\/td><td><strong>Med CBT\u2011i<\/strong>, a digital therapeutic for insomnia<\/td><\/tr><tr><td>Original Agreement<\/td><td>Commercialization agreement entered in 2021<\/td><\/tr><tr><td>Announcement Date<\/td><td>26 Aug 2026<\/td><\/tr><tr><td>Next Steps<\/td><td>Not specified in the announcement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-partnership-timeline-amp-background\" class=\"wp-block-heading\">Partnership Timeline &amp; Background<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2021:<\/strong> Shionogi and SUSMED entered a commercialization agreement covering SUSMED&#8217;s digital insomnia therapy.<\/li>\n\n\n\n<li><strong>Aug 2023:<\/strong> SUSMED&#8217;s Med CBT\u2011i insomnia application was approved by <strong>Japan&#8217;s Ministry of Health, Labour and Welfare (MHLW)<\/strong> to deliver cognitive behavioral therapy for insomnia (CBT\u2011I) to patients.<\/li>\n\n\n\n<li><strong>Aug 2026:<\/strong> Shionogi announced the termination of the collaboration.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-product-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Product Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Product:<\/strong> Med CBT\u2011i, a prescription digital therapeutic application<\/li>\n\n\n\n<li><strong>Indication:<\/strong> Insomnia<\/li>\n\n\n\n<li><strong>Modality:<\/strong> Software\u2011delivered cognitive behavioral therapy for insomnia (CBT\u2011I), the first\u2011line, non\u2011pharmacological standard of care for chronic insomnia<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> Approved by Japan&#8217;s MHLW in August 2023<\/li>\n\n\n\n<li><strong>Treatment Regimen:<\/strong> Patients follow treatments prompted by the product over a 9\u2011week period<\/li>\n\n\n\n<li><strong>Therapeutic Effect:<\/strong> Achieves therapeutic effects for insomnia symptoms through structured, app\u2011guided CBT\u2011I<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Reassessment:<\/strong> The termination signals Shionogi&#8217;s withdrawal from the commercialization of digital therapeutics for insomnia, refocusing its portfolio priorities.<\/li>\n\n\n\n<li><strong>Japan&#8217;s DTx Landscape:<\/strong> The split tests the commercial viability of prescription digital therapeutics in Japan, where reimbursement and adoption models remain nascent despite the pioneering MHLW approval of Med CBT\u2011i in 2023.<\/li>\n\n\n\n<li><strong>Impact on SUSMED:<\/strong> SUSMED will need to pursue commercialization of Med CBT\u2011i independently or with a new partner, making upcoming adoption and revenue metrics a key watch item for investors in TYO: 4263.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> Any further commentary from either company on the operational and financial implications of the termination, and the future strategic path for the Med CBT\u2011i franchise.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief is for informational purposes only and does not constitute investment, medical, or regulatory advice. Statements regarding future commercialization and market development are forward\u2011looking and subject to risks and uncertainties; actual results may differ materially. Refer to official announcements from Shionogi and SUSMED for authoritative details.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shionogi &amp; Co., Ltd. (TYO: 4507) announced that it has terminated its collaboration with SUSMED&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1],"tags":[423,4910,2673],"class_list":["post-76765","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-shionogi","tag-susmed","tag-tyo-4507"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT\u2011i - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shionogi &amp; Co., Ltd. (TYO: 4507) announced that it has terminated its collaboration with SUSMED Co., Ltd. (TYO: 4263) regarding a digital therapeutic for insomnia. The two companies originally entered into a commercialization agreement for the therapy in 2021, centered on SUSMED&#039;s Med CBT\u2011i application, which delivers cognitive behavioral therapy for insomnia (CBT\u2011I) to patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76765\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT\u2011i\" \/>\n<meta property=\"og:description\" content=\"Shionogi &amp; Co., Ltd. (TYO: 4507) announced that it has terminated its collaboration with SUSMED Co., Ltd. (TYO: 4263) regarding a digital therapeutic for insomnia. The two companies originally entered into a commercialization agreement for the therapy in 2021, centered on SUSMED&#039;s Med CBT\u2011i application, which delivers cognitive behavioral therapy for insomnia (CBT\u2011I) to patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76765\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T04:29:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76765#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76765\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT\u2011i\",\"datePublished\":\"2026-08-27T04:29:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76765\"},\"wordCount\":415,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Shionogi\",\"SUSMED\",\"TYO: 4507\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76765#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76765\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76765\",\"name\":\"Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT\u2011i - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-27T04:29:21+00:00\",\"description\":\"Shionogi & Co., Ltd. (TYO: 4507) announced that it has terminated its collaboration with SUSMED Co., Ltd. (TYO: 4263) regarding a digital therapeutic for insomnia. The two companies originally entered into a commercialization agreement for the therapy in 2021, centered on SUSMED's Med CBT\u2011i application, which delivers cognitive behavioral therapy for insomnia (CBT\u2011I) to patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76765#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76765\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76765#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT\u2011i\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT\u2011i - Insight, China&#039;s Pharmaceutical Industry","description":"Shionogi & Co., Ltd. (TYO: 4507) announced that it has terminated its collaboration with SUSMED Co., Ltd. (TYO: 4263) regarding a digital therapeutic for insomnia. The two companies originally entered into a commercialization agreement for the therapy in 2021, centered on SUSMED's Med CBT\u2011i application, which delivers cognitive behavioral therapy for insomnia (CBT\u2011I) to patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76765","og_locale":"en_US","og_type":"article","og_title":"Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT\u2011i","og_description":"Shionogi & Co., Ltd. (TYO: 4507) announced that it has terminated its collaboration with SUSMED Co., Ltd. (TYO: 4263) regarding a digital therapeutic for insomnia. The two companies originally entered into a commercialization agreement for the therapy in 2021, centered on SUSMED's Med CBT\u2011i application, which delivers cognitive behavioral therapy for insomnia (CBT\u2011I) to patients.","og_url":"https:\/\/flcube.com\/?p=76765","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-27T04:29:21+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76765#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76765"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT\u2011i","datePublished":"2026-08-27T04:29:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76765"},"wordCount":415,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Shionogi","SUSMED","TYO: 4507"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76765#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76765","url":"https:\/\/flcube.com\/?p=76765","name":"Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT\u2011i - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-27T04:29:21+00:00","description":"Shionogi & Co., Ltd. (TYO: 4507) announced that it has terminated its collaboration with SUSMED Co., Ltd. (TYO: 4263) regarding a digital therapeutic for insomnia. The two companies originally entered into a commercialization agreement for the therapy in 2021, centered on SUSMED's Med CBT\u2011i application, which delivers cognitive behavioral therapy for insomnia (CBT\u2011I) to patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76765#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76765"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76765#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shionogi Terminates Collaboration with SUSMED on Digital Insomnia Therapy Med CBT\u2011i"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76765"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76765\/revisions"}],"predecessor-version":[{"id":76766,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76765\/revisions\/76766"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}